Shah MA - Search Results

1

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE. Janjigian YY, et al. Among authors: shah ma. Ann Oncol. 2012 Oct;23(10):2656-2662. doi: 10.1093/annonc/mds104. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689179 Free article.

2

[Postoperative adjuvant chemoradiotherapy in high risk stomach carcinoma].

Shah MA, Kelsen DP. Shah MA, et al. Chirurg. 2002 Apr;73(4):325-30. doi: 10.1007/s00104-002-0459-8. Chirurg. 2002. PMID: 12063916 German.

3

Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases.

Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP. Brenner B, et al. Among authors: shah ma. Br J Cancer. 2004 May 4;90(9):1720-6. doi: 10.1038/sj.bjc.6601758. Br J Cancer. 2004. PMID: 15150595 Free PMC article.

4

Combined modality therapy of esophageal cancer: changes in the standard of care?

Shah MA, Kelsen DP. Shah MA, et al. Ann Surg Oncol. 2004 Jul;11(7):641-3. doi: 10.1245/ASO.2004.04.907. Epub 2004 Jun 14. Ann Surg Oncol. 2004. PMID: 15197008 No abstract available.

5

Treatment of metastatic esophagus and gastric cancer.

Shah MA, Schwartz GK. Shah MA, et al. Semin Oncol. 2004 Aug;31(4):574-87. doi: 10.1053/j.seminoncol.2004.04.013. Semin Oncol. 2004. PMID: 15297948 Review.

6

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Chung KY, et al. J Clin Oncol. 2005 Mar 20;23(9):1803-10. doi: 10.1200/JCO.2005.08.037. Epub 2005 Jan 27. J Clin Oncol. 2005. PMID: 15677699

7

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

Kortmansky J, Shah MA, Kaubisch A, Weyerbacher A, Yi S, Tong W, Sowers R, Gonen M, O'reilly E, Kemeny N, Ilson DI, Saltz LB, Maki RG, Kelsen DP, Schwartz GK. Kortmansky J, et al. Among authors: shah ma. J Clin Oncol. 2005 Mar 20;23(9):1875-84. doi: 10.1200/JCO.2005.03.116. Epub 2005 Feb 7. J Clin Oncol. 2005. PMID: 15699481 Clinical Trial.

8

Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.

Shah MA, Ilson D, Kelsen DP. Shah MA, et al. J Clin Oncol. 2005 Apr 10;23(11):2574-6. doi: 10.1200/JCO.2005.81.908. Epub 2005 Mar 28. J Clin Oncol. 2005. PMID: 15795413 Clinical Trial. No abstract available.

9

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.

Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK. Shah MA, et al. Clin Cancer Res. 2005 May 15;11(10):3836-45. doi: 10.1158/1078-0432.CCR-04-2651. Clin Cancer Res. 2005. PMID: 15897584 Clinical Trial.

10

Gastric cancer: an update.

Shah MA. Shah MA. Curr Oncol Rep. 2006 May;8(3):183-91. doi: 10.1007/s11912-006-0018-4. Curr Oncol Rep. 2006. PMID: 16618382 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,037 results

Search Page